Description: TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Home Page: www.tcbiopharm.com
TCBP Technical Analysis
Maxim 1
Motherwell,
ML1 4WR
United Kingdom
Phone:
44 14 1433 7557
Officers
| Name | Title |
|---|---|
| Dr. Michael Leek M.B.A., Ph.D. | Co-Founder & Exec. Chairman |
| Mr. Bryan L. Kobel | CEO & Director |
| Ms. Angela Scott | Co-Founder & COO |
| Mr. Martin E. Thorp | CFO & Director |
| Mr. Christopher Camarra | Exec. VP of Communications |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 137.0788 |
| Price-to-Sales TTM: | 84.9731 |
| IPO Date: | 2022-02-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 76 |